Literature DB >> 11588518

Inhibition of HIV replication by A77 1726, the active metabolite of leflunomide, in combination with pyrimidine nucleoside reverse transcriptase inhibitors.

M M Hossain, D M Margolis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588518     DOI: 10.1097/00042560-200110010-00016

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  4 in total

Review 1.  Rheumatic manifestations of human immunodeficiency virus.

Authors:  Alan M Solinger
Journal:  Curr Rheumatol Rep       Date:  2003-06       Impact factor: 4.592

2.  Persistent immune activation in chronic HIV infection: do any interventions work?

Authors:  Reena Rajasuriar; Gabriela Khoury; Adeeba Kamarulzaman; Martyn A French; Paul U Cameron; Sharon R Lewin
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

3.  The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants.

Authors:  Sarah W Read; Mary DeGrezia; Emily J Ciccone; Rebecca DerSimonian; Jeanette Higgins; Joseph W Adelsberger; Judith M Starling; Catherine Rehm; Irini Sereti
Journal:  PLoS One       Date:  2010-08-03       Impact factor: 3.240

4.  Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review.

Authors:  Y C Tsai; T F Tsai
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-09-03       Impact factor: 5.346

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.